1 study on Lixisenatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
If GLP-1R agonists are found to significantly reduce Lipoprotein(a) (Lp(a)) levels, it would represent a substantial advancement in managing cardiovascular risk for Type 2 Diabetes patients. This finding would add a n…